Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Carbonic anhydrase IX (CA IX) is a hypoxia-regulated enzyme, overexpressed in many types of human cancer. CA IX is involved in pH homeostasis, contributing to extracellular acidification and tumourigenesis. Acidification of the extracellular milieu can impact upon cellular uptake of chemotherapeutic drugs by favouring weak acids (e.g. melphalan), but limiting access of weak bases (e.g. doxorubicin). We investigated whether alterations of CA IX activity affected anti-cancer drug uptake and toxicity. CA inhibitor acetazolamide (AZM) enhanced doxorubicin toxicity but reduced melphalan toxicity in cell lines that highly expressed CA IX under anoxic conditions (HT29 and MDA435 CA9/18). The toxicity changes reflected modification of passive drug uptake. AZM did not alter toxicity or uptake in cells with low CA IX activity (HCT116 and MDA435 EV1). AZM lowered intracellular pH in HT29 and MDA435 CA9/18 cells under anoxic conditions. CA IX activity has chemomodulatory properties and is an attractive target for anti-cancer therapy.

Original publication

DOI

10.3109/14756366.2012.736979

Type

Journal article

Journal

J Enzyme Inhib Med Chem

Publication Date

04/2013

Volume

28

Pages

360 - 369

Keywords

Antineoplastic Agents, Carbonic Anhydrase Inhibitors, Carbonic Anhydrases, Dose-Response Relationship, Drug, Doxorubicin, Drug Screening Assays, Antitumor, HCT116 Cells, HT29 Cells, Humans, Melphalan, Molecular Structure, Neoplasms, Protein Isoforms, Structure-Activity Relationship, Tumor Cells, Cultured